HIV/AIDS and STDs: A Comprehensive Pharmacological Review for Clinicians

Every year, the United States reports over 1.2 million new HIV infections, yet for many patients, HIV remains an invisible partner in a cascade of sexually transmitted diseases (STDs). In 2023, 20% of newly diagnosed HIV cases co‑occurred with syphilis, underscoring the intertwined epidemiology of these infections. For pharmacy and medical students, mastering the pharmacology of antiretroviral therapy (ART) and STD therapeutics is not merely academic—it directly influences patient outcomes, adherence, and public health interventions.

Introduction and Background

Human Immunodeficiency Virus (HIV) is a retrovirus that targets CD4+ T lymphocytes, leading to progressive immunodeficiency and the eventual development of Acquired Immunodeficiency Syndrome (AIDS). The first cases of AIDS were identified in the early 1980s, and since then, the epidemiology of HIV has evolved dramatically. While heterosexual transmission remains the predominant route in many regions, men who have sex with men (MSM) and people who inject drugs (PWID) continue to bear a disproportionate burden. Concurrently, the incidence of syphilis, gonorrhea, chlamydia, and herpes simplex virus (HSV) infections has risen, particularly among MSM, fueling a complex clinical landscape where HIV and other STDs coexist and interact.

Pharmacologically, ART is divided into five major classes: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), non‑nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and entry/fusion inhibitors. These agents target distinct stages of the viral life cycle—from reverse transcription to integration and budding—providing a multi‑layered blockade that reduces viral replication to undetectable levels when adherence is optimal. STD treatment, on the other hand, relies heavily on antibiotics (e.g., penicillin for syphilis, ceftriaxone for gonorrhea) and antivirals (e.g., acyclovir for HSV), each with well‑characterized mechanisms and resistance profiles.

Mechanism of Action

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/NtRTIs)

These analogues mimic natural nucleosides or nucleotides and are incorporated into viral DNA by reverse transcriptase. Once incorporated, they lack a 3’‑OH group, causing chain termination and preventing further elongation of the viral genome. Key examples include zidovudine (AZT), lamivudine (3TC), and tenofovir alafenamide (TAF). Their binding is highly specific to the reverse transcriptase active site, and resistance often arises from mutations that reduce drug incorporation.

Non‑Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

NNRTIs bind to a hydrophobic pocket adjacent to the active site of reverse transcriptase, inducing a conformational change that allosterically inhibits enzyme activity. Efavirenz and rilpivirine are classic NNRTIs. Because they do not compete with natural nucleotides, resistance mutations typically involve changes in the NNRTI binding pocket.

Protease Inhibitors (PIs)

HIV protease cleaves the Gag‑Pol polyprotein into functional structural and enzymatic proteins necessary for virion maturation. PIs, such as lopinavir/ritonavir, competitively inhibit the protease active site, resulting in immature, non‑infectious viral particles. Ritonavir acts primarily as a pharmacokinetic enhancer by inhibiting CYP3A4, boosting plasma concentrations of co‑administered PIs.

Integrase Strand Transfer Inhibitors (INSTIs)

Integrase catalyzes the insertion of viral DNA into the host genome. INSTIs, including dolutegravir and bictegravir, chelate divalent metal ions (Mg²⁺/Mn²⁺) in the integrase active site, blocking strand transfer. Resistance mutations cluster in the strand transfer active site, conferring cross‑resistance across the class.

Entry/Fusion Inhibitors

These agents target the early stages of viral entry. Enfuvirtide is a fusion inhibitor that binds to gp41, preventing the conformational change required for membrane fusion. Maraviroc is a CCR5 antagonist that blocks the CCR5 co‑receptor on host cells, inhibiting viral entry for R5‑tropic strains.

Antibiotic and Antiviral Mechanisms for Common STDs

Penicillin G and benzathine penicillin target the bacterial cell wall by inhibiting transpeptidase activity, effectively treating syphilis. Ceftriaxone, a third‑generation cephalosporin, blocks transpeptidase and is the first‑line therapy for gonorrhea. Azithromycin, a macrolide, binds the 50S ribosomal subunit, inhibiting protein synthesis. For HSV, acyclovir is a nucleoside analogue that, once phosphorylated by viral thymidine kinase, inhibits viral DNA polymerase and causes chain termination.

Clinical Pharmacology

The pharmacokinetics of ART vary by class but share common themes: high oral bioavailability, extensive tissue penetration, and reliance on hepatic metabolism (often via CYP3A4). Below is a comparison of key PK/PD parameters for selected agents.

Pharmacodynamic considerations include the therapeutic window and dose‑response relationship. For example, the goal of ART is to achieve an undetectable viral load (<200 copies/mL) while maintaining CD4+ counts above 200 cells/µL. The dose of tenofovir disoproxil fumarate (TDF) is 300 mg daily, whereas TAF is dosed at 25 mg daily due to its higher potency and lower systemic exposure.

Therapeutic Applications

• HIV Infection: First‑line regimens typically consist of two NRTIs (e.g., TAF/FTC) plus a single agent from INSTI (dolutegravir) or NNRTI (efavirenz). Combination therapy reduces the risk of resistance and improves tolerability.

• Pre‑Exposure Prophylaxis (PrEP): Tenofovir disoproxil fumarate/emtricitabine (Truvada) or tenofovir alafenamide/emtricitabine (Descovy) daily for high‑risk individuals.

• Post‑Exposure Prophylaxis (PEP): A 28‑day course of TDF/FTC plus an INSTI (dolutegravir) or NNRTI (efavirenz) initiated within 72 h of exposure.

• Syphilis: Benzathine penicillin G 2.4 MU IM once for early disease; 4.8 MU IM for late or complicated disease.

• Gonorrhea: Ceftriaxone 250 mg IM single dose plus azithromycin 1 g PO single dose (dual therapy).

• Chlamydia: Azithromycin 1 g PO single dose or doxycycline 100 mg PO BID for 7 days.

• HSV: Acyclovir 400 mg PO BID for 7 days for primary infection; 200 mg BID for suppressive therapy.

Off‑label uses are emerging, such as dolutegravir for hepatitis B co‑infection due to its activity against HBV polymerase. In pediatric populations, dosing is weight‑based (e.g., TDF 1.8 mg/kg once daily). Geriatric patients require caution with drugs that have renal clearance; dose adjustments for TDF/FTC are based on creatinine clearance. Pregnancy: TDF/FTC is category B; dolutegravir has limited data but is generally avoided in the first trimester due to potential teratogenicity.

Adverse Effects and Safety

Common side effects and their approximate incidence:

• Tenofovir disoproxil fumarate – renal dysfunction (5–10%) and bone mineral density loss (10–15%).

• Zidovudine – anemia (20–30%) and neutropenia (10%).

• Efavirenz – central nervous system (CNS) effects (rash, vivid dreams) in ~30% of patients.

• Dolutegravir – weight gain (10–15%) and mild CNS symptoms (5%).

• Enfuvirtide – injection site reactions (up to 50%) and hyperglycemia (5%).

Black box warnings include:

• Efavirenz – CNS toxicity and potential teratogenicity.

• Tenofovir disoproxil fumarate – renal tubular dysfunction and osteopenia.

• Enfuvirtide – injection site reactions and metabolic effects.

Drug interactions are frequent due to CYP3A4 metabolism. The following table highlights major interactions.

Monitoring parameters include CBC, renal and hepatic panels, lipid profiles, and viral load. Contraindications: hypersensitivity to the drug, severe hepatic impairment (for drugs metabolized by the liver), and pregnancy for efavirenz.

Clinical Pearls for Practice

• “START” the patient on a single‑tablet regimen whenever possible to improve adherence and reduce pill burden.

• “CATCH” the renal function early; adjust tenofovir dose if eGFR < 60 mL/min/1.73 m².

• “PILL” the patient with a reminder system; consider a daily electronic reminder to minimize missed doses.

• “SYN” the patient’s medication list for potential CYP3A4 interactions before adding efavirenz or ritonavir.

• “STOP” the use of efavirenz in the first trimester; switch to dolutegravir if possible.

• “BONE” the patient’s bone density if on TDF for >6 months; switch to TAF to mitigate risk.

• “GOLD” the fact that dual therapy for gonorrhea (ceftriaxone + azithromycin) remains the standard until resistance patterns change.

Comparison Table

Exam‑Focused Review

Common question stems:

• Which antiretroviral class is most likely to cause nephrotoxicity?

• What is the first‑line treatment for early syphilis in a patient with penicillin allergy?

• Which drug requires dose adjustment in renal impairment and is also used for PrEP?

• Identify the drug that is contraindicated in the first trimester of pregnancy.

• Which STD therapy is recommended for a patient who is allergic to macrolides?

Key differentiators students often confuse:

• Efavirenz vs. Rilpivirine: efavirenz has CNS toxicity; rilpivirine requires a CYP3A4 inducer/ inhibitor for optimal absorption.

• Tenofovir disoproxil fumarate vs. Tenofovir alafenamide: TDF has higher systemic exposure and renal toxicity; TAF is more potent with lower toxicity.

• Dolutegravir vs. Bictegravir: both INSTIs, but bictegravir has a higher barrier to resistance and a longer half‑life.

Must‑know facts for NAPLEX/USMLE/clinical rotations:

• All ART must be started within 7 days of diagnosis to reduce morbidity.

• PrEP requires baseline HIV testing, renal function, and hepatitis B screening.

• Syphilis serology: VDRL/RPR for screening; confirm with TPPA/FTA‑ABS.

• Gonorrhea treatment: dual therapy with ceftriaxone 250 mg IM + azithromycin 1 g PO.

• HSV suppressive therapy: acyclovir 400 mg PO BID; valacyclovir 500 mg PO BID for better adherence.

Key Takeaways

1. Antiretroviral therapy must be initiated promptly and maintained with high adherence to achieve viral suppression.

2. Tenofovir alafenamide offers a safer renal profile compared to tenofovir disoproxil fumarate.

3. Dual therapy for gonorrhea remains the standard until widespread resistance emerges.

4. Drug interactions via CYP3A4 and UGT1A1 are common; careful medication reconciliation is essential.

5. Pregnancy considerations: avoid efavirenz in the first trimester; use dolutegravir with caution.

6. PrEP dosing: TDF/FTC daily; ensure hepatitis B screening and renal assessment.

7. Adverse effects: monitor for renal dysfunction, bone density loss, CNS toxicity, and injection site reactions.

8. Clinical pearls such as single‑tablet regimens, reminder systems, and renal monitoring can improve outcomes.

9. Syphilis diagnosis relies on both non‑treponemal and treponemal tests; treatment is based on disease stage.

10. Regular viral load monitoring (every 3–6 months) is critical to detect virologic failure early.

“In the battle against HIV/AIDS and co‑existing STDs, the pharmacist’s role extends beyond dispensing—it's about ensuring safe, effective, and patient‑centered therapy that curtails disease progression and transmission.”